Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity.
|
29367945 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD-19 CAR-T cells have been recently approved for high-risk R/R ALL and lymphoma.
|
29544528 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Early trials with anti-CD19 CAR T cells have achieved spectacular remissions in B-cell leukemia and lymphoma, so far refractory, very recently resulting in the Food and Drug Administration approval of CD19 CAR T cells for therapy.
|
29620951 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CARCIK-CD19 showed a dose-dependent antitumor response and prolonged persistence in a PDX, bearing the feature of a Philadelphia-like ALL with PAX5/AUTS2 translocation, and in a survival model of lymphoma, achieving complete eradication of disseminated tumors.
|
29641322 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that Igβ and CD19 are part of an alternative B-cell signaling module that use continuous ITAM/PI3K signaling to promote the survival of B lymphoma and normal B cells.
|
29669863 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In CAR T cell therapy targeting CD19 for lymphoma, host immune anti-murine CAR responses limited the efficacy of repeat dosing and possibly long-term persistence.
|
29678657 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Food and Drug Administration has approved CAR T cells that target CD19 for treatment of advanced B cell leukemia and lymphoma.
|
29685162 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to treat lymphoma, monoclonal antibodies (mAb) can target different antigens, including CD19, CD20 and CD22 on the surface of B-cells.
|
29922424 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.
|
30097433 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a clinical trial to assess the safety and efficacy of CD19-targeting CAR-T-cells in the treatment of relapsed and chemotherapy-refractory B-ALL and lymphoma.
|
30198955 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to recent developments in therapeutic engineered T cell and effective responses of CD19-directed chimeric antigen receptor T cells (CART19) in patients with B-cell leukemia and lymphoma, adoptive T cell immunotherapy, particularly CAR-T cell therapy became a rapidly growing field in cancer therapy and recently Kymriah and Yescarta (CD19-directed CAR-T cells) were approved by FDA.
|
30261221 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TG2P also potentiated the CD19-targeted, chimeric antigen receptor (CAR)-modified T cells to kill Raji B-lymphoma cells.
|
30524895 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
T cell immunotherapies are promising options in leukemia, among which the CD19/CD3-bispecific T cell engager antibody blinatumomab (MT103) has shown high response rates at very low doses in patients with lymphoma.
|
30611570 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CAR-expressing T cells against CD19 can cause curative effects in leukemia and lymphoma and is approved for clinical use.
|
30622115 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CAR T cells have revolutionized the treatment of relapsed and refractory CD19-positive leukemia and lymphoma.
|
30680777 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tisagenlecleucel (kymriah, Novartis) is an autologous CD19-targeted CAR T cell product approved for treatment of R/R B cell ALL and lymphoma.
|
30764841 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autologous T cells transduced with CD19-directed chimeric antigen receptors have recently been approved by several regulatory agencies for the treatment of relapsed and refractory leukemia and lymphoma, after demonstrating remarkable remission rate in advanced patients.
|
30809033 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this regard, CD19-specific CAR T cell therapies have achieved dramatic objective responses for a high percent of patients with CD19-positive leukemia or lymphoma.
|
30828333 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19 chimeric antigen receptor (CAR) T cell therapy has changed the outcomes of relapsed/refractory B‑cell leukemia and lymphoma.
|
30942469 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma.
|
31372000 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two Anti-CD19 CAR-T therapies have been approved for the treatment of CD19-positive leukemia or lymphoma.
|
31429760 |
2019 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
|
31439577 |
2019 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this article is to provide consensus opinion from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the use of CD19 CAR T cell products for the treatment of NHL.
|
31446199 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy has changed the typical outcomes of relapsed/refractory B-cell leukemia and lymphoma.
|
31611950 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
|
31690821 |
2019 |